Highlights
- The first patient in the Phase 1/2 clinical trial of CHM CDH17 has been dosed at the Sarah Cannon Research Institute in Tennessee.
- Patient recruitment for this first-in-human clinical trial is currently underway at cancer centers across the United States.
- Phase 1 of the trial aims to enrol 15 patients.
Chimeric Therapeutics Limited (ASX:CHM) has reached a significant milestone in its Phase 1/2 clinical trial of CDH17-directed CAR-T cell therapy with the dosing of the first patient at Sarah Cannon Research Institute in Tennessee, the United States.
CHM CDH17 is a third generation CAR T cell therapy targeting CDH17, a cancer marker associated with poor prognosis and metastasis in gastrointestinal tumours. Recruitment for this two-stage, first-in-human clinical trial is progressing at cancer centres across the United States.
Data source: Company update
Phase 1 of this trial is anticipated to enrol 15 patients and will include dose selection and expansion with indication-specific Phase 2 cohorts.
Data source: Company update
CHM shares trade higher
CHM shares traded at AU$0.017 apiece, up more than 6%, at the time of writing on 28 August 2024.